News

The US's decision to impose tariffs on steel and aluminum has sparked international backlash, with the UK considering retaliatory measures while the EU has already announced countermeasures. The situation has created uncertainty for businesses on both sides of the Atlantic, with the UK government committed to negotiating a new economic pact with the US while reserving the right to retaliate if necessary.

The cryptocurrency market is experiencing mixed signals, with Bitcoin and Ethereum struggling to maintain gains while XRP rallies on optimism over the SEC potentially closing its case against Ripple. Despite these challenges, some analysts remain optimistic about Bitcoin's future, predicting it will reach $200,000 by the end of 2025.

The U.S. Securities and Exchange Commission is unlikely to approve or reject any new crypto ETFs until its new leadership is confirmed, delaying decisions on spot ETFs for several cryptocurrencies. Despite the delays, analysts estimate a high probability of approval for some altcoin ETFs by the end of the year, with Polymarket data showing a 76% chance for a Litecoin ETF and an 88% chance for a Solana ETF.

Rubrik Inc. (RBRK) stock received a Buy rating and a $77 price target from Rosenblatt analyst Blair Abernethy, citing the company's strong product position and growth potential in the data management and security markets. This upgrade comes ahead of Rubrik's fourth-quarter fiscal 2025 earnings report, expected to show continued revenue growth and a shift towards subscription-based services.

ViiV Healthcare's EMBRACE phase 2b study found that N6LS, a novel long-acting HIV capsid inhibitor, effectively suppressed viral levels in adults living with HIV when combined with monthly cabotegravir long-acting. The company also presented positive data from two phase 2a studies of investigational antiretroviral therapies, VH184 and VH499.